News Quantified

RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Invesco Health Care Fund Q3 2025 Commentary [Seeking Alpha]

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

-7.5%

MISS

-3.7%

MISS

8.4%

MISS

0.1%

MISS

Form S-8 RHYTHM PHARMACEUTICALS,

Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 09

Form 8-K RHYTHM PHARMACEUTICALS, For: Dec 16

Form 4 RHYTHM PHARMACEUTICALS, For: Dec 11 Filed by: Cramer Pamela J.

Form 144 RHYTHM PHARMACEUTICALS, Filed by: Cramer Pamela J.

Top News Gainers

8/7 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities 14.9%

3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%

10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%

10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%

4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%

11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%

3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%

12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%

2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%

3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%

Top News Decliners

8/7 Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 07 -9.8%

9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%

1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%

2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%

4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%

4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%

3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%

7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%

6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%

1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day